
Around-the-clock news and analysis of regulatory, legal, and financial developments.

Daily commentary on biopharma business development, R&D, financing, marketing, and policy news.

Analysis of European biopharma business development, finance, strategy, drug development, regulation, & reimbursement.

The leading source for in- depth news and analysis of the medtech and diagnostics industries.

In-depth news and analysis of the OTC drug, dietary supplement and personal care industries.

Insightful analysis to help you comply with U.S. and international pharmaceutical manufacturing QA/QC requirements.

Weekly, in-depth coverage of the medical device and diagnostic industries.

The premier strategic business resource for the biopharma, medtech, and diagnostics industries.

Quality content on medical technologies impacting the spectrum of surgical, orthopedic, cardiovascular, and other markets.

Highly specialized industry insight on the Asian marketplace, plus editor’s picks from the world press and English summaries of Chinese and Japanese news

In-depth coverage of U.S. drug approvals, including FDA approval actions by classification.

Expert, in-depth analysis of biopharma regulatory, legislative, legal and business developments.

Daily, in-depth analysis of the key developments shaping the biopharma industry.

Specialized coverage of regulatory, legislative, scientific, retailer/e-tailer, financial, marketing and legal news across the cosmetics, skin-care and fragrance industries.

Actionable insight on regulation, policy, FDA and CMS to apply directly to your decision-making.

In-depth news and analysis of FDA's interpretation and enforcement of the Quality System Regulation.

In-depth profiles of leading-edge companies and technologies, including the most important new trends in the biopharma, medtech and diagnostics industries.

In-depth news and analysis of the nonprescription pharmaceutical and dietary supplement industries.

Online daily coverage of health care issues including prescription and non-prescription pharmaceuticals and federal health policy.